Alzamend Stock Analysis

ALZN -  USA Stock  

USD 0.88  0.05  5.38%

The big decline in price over the last few months for Alzamend Neuro could raise concerns from institutional investors as the firm is trading at a share price of 0.88 on 364,553 in volume. The company executives failed to add value to investors and position the firm supply of money to exploit market volatility in April. However, diversifying your holdings with Alzamend Neuro or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.05. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Alzamend Neuro partners.
Please continue to Trending Equities.
The Alzamend Neuro stock analysis report makes it easy to digest most publicly released information about Alzamend Neuro and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Alzamend Stock analysis module also helps to analyze the Alzamend Neuro price relationship with some important fundamental indicators such as market cap and management efficiency.

Alzamend Stock Analysis Notes

About 49.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.11. Alzamend Neuro had not issued any dividends in recent years. Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia. Alzamend Neuro operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. For more info on Alzamend Neuro please contact the company at 844 722 6333 or go to

Alzamend Neuro Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Alzamend Neuro's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Alzamend Neuro or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Alzamend Neuro generated a negative expected return over the last 90 days
Alzamend Neuro has high historical volatility and very poor performance
Alzamend Neuro has some characteristics of a very speculative penny stock
Alzamend Neuro has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (9.75 M).
Alzamend Neuro currently holds about 11.79 M in cash with (6.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.13.
Alzamend Neuro has a frail financial position based on the latest SEC disclosures
Roughly 49.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Alzamend Neuro exotic insider transaction detected

Alzamend Largest EPS Surprises

Earnings surprises can significantly impact Alzamend Neuro's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Alzamend Neuro SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Alzamend Neuro prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Alzamend Neuro investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Alzamend Neuro specific information freely available to individual and institutional investors to make a timely investment decision.
28th of April 2022
Unclassified Corporate Event
20th of April 2022
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
18th of April 2022
Financial Statements and Exhibits. Regulation FD Disclosure
17th of December 2021
Financial Statements and Exhibits. Regulation FD Disclosure
30th of September 2021
Financial Statements and Exhibits. Regulation FD Disclosure
17th of August 2021
Financial Statements and Exhibits. Regulation FD Disclosure
4th of August 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Unclassified Corporate Event
28th of July 2021
Financial Statements and Exhibits. Regulation FD Disclosure

Alzamend Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Alzamend Neuro is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alzamend Neuro backward and forwards among themselves. Alzamend Neuro's institutional investor refers to the entity that pools money to purchase Alzamend Neuro's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Truist Financial CorpCommon Shares2.3 M2.8 M
Rfg Advisory LlcCommon Shares250 K308 K
Millennium Management LlcCommon Shares142.4 K175 K
Marshall Wace LlpCommon Shares124.1 K154 K
Group One Trading LpCall Options119.5 K147 K
Qube Research Technologies LtdCommon Shares78.5 K97 K
Susquehanna International Group LlpCommon Shares58 K71 K
Geode Capital Management LlcCommon Shares40.6 K49 K
Citadel Advisors LlcPut Options37.1 K46 K
Note, although Alzamend Neuro's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Alzamend Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 86.04 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Alzamend Neuro's market, we take the total number of its shares issued and multiply it by Alzamend Neuro's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Alzamend Profitablity

Alzamend Neuro's profitability indicators refer to fundamental financial ratios that showcase Alzamend Neuro's ability to generate income relative to its revenue or operating costs. If, let's say, Alzamend Neuro is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Alzamend Neuro's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Alzamend Neuro's profitability requires more research than a typical breakdown of Alzamend Neuro's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(2.46) (2.65) 
Return on Average Equity(4.10) (4.42) 
Return on Invested Capital(9.77) (10.54) 

Management Efficiency

The entity has return on total asset (ROA) of (91.33) % which means that it has lost $91.33 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (182.81) %, meaning that it created substantial loss on money invested by shareholders. Alzamend Neuro management efficiency ratios could be used to measure how well alzamend neuro manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -2.65. The value of Return on Average Equity is estimated to slide to -4.42. The value of Total Assets is estimated to slide to about 3 M. The value of Current Assets is estimated to slide to about 3 M
Last ReportedProjected for 2022
Book Value per Share 0.0322  0.0256 
Tangible Assets Book Value per Share 0.046  0.0417 
Tangible Asset Value3.3 MM

Technical Drivers

As of the 24th of May, Alzamend Neuro shows the mean deviation of 4.89, and Risk Adjusted Performance of (0.12). Alzamend Neuro technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Alzamend Neuro, which can be compared to its rivals. Please confirm Alzamend Neuro jensen alpha and downside variance to decide if Alzamend Neuro is priced correctly, providing market reflects its regular price of 0.88 per share. Given that Alzamend Neuro is a hitting penny stock territory we recommend to closely look at its total risk alpha.

Alzamend Neuro Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Mid-point over period is an average of Alzamend Neuro highest and lowest values attained during the given period.

Alzamend Neuro Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alzamend Neuro insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alzamend Neuro's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alzamend Neuro insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Alzamend Neuro Predictive Daily Indicators

Alzamend Neuro intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Alzamend Neuro stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Alzamend Neuro Forecast Models

Alzamend Neuro time-series forecasting models is one of many Alzamend Neuro's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Alzamend Neuro's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Alzamend Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Alzamend Neuro stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Alzamend shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Alzamend Neuro. By using and applying Alzamend Stock analysis, traders can create a robust methodology for identifying Alzamend entry and exit points for their positions.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimers and other neurodegenerative diseases, and psychiatric disorders and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patients immunological system to combat Alzheimers. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Current Alzamend Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Alzamend analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Alzamend analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Alzamend Neuro current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Alzamend analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Alzamend stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Alzamend Neuro, talking to its executives and customers, or listening to Alzamend conference calls.
Alzamend Analyst Advice Details

Alzamend Stock Analysis Indicators

Alzamend Neuro stock analysis indicators help investors evaluate how Alzamend Neuro stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Alzamend Neuro shares will generate the highest return on investment. By understating and applying Alzamend Neuro stock analysis, traders can identify Alzamend Neuro position entry and exit signals to maximize returns.
Shares Percent Shares Out1.72%
Quick Ratio25.25
Fifty Two Week Low0.8010
Short Percent Of Float2.55%
Forward Price Earnings-4.87
Float Shares51.49M
Fifty Two Week High33.5500
Shares Short Prior Month827.86k
Average Daily Volume Last 10 Day626.03k
Average Daily Volume In Three Month1.31M
Fifty Day Average1.0494
Two Hundred Day Average1.9698
Please continue to Trending Equities. Note that the Alzamend Neuro information on this page should be used as a complementary analysis to other Alzamend Neuro's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Alzamend Stock analysis

When running Alzamend Neuro price analysis, check to measure Alzamend Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alzamend Neuro is operating at the current time. Most of Alzamend Neuro's value examination focuses on studying past and present price action to predict the probability of Alzamend Neuro's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Alzamend Neuro's price. Additionally, you may evaluate how the addition of Alzamend Neuro to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Is Alzamend Neuro's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine Alzamend Neuro value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.